Skip to main content

Mussallem Michael A's Form 4 filing

Edwards Lifesciences Corp (EW) · filed May 10, 2022

Accession no.
0001225208-22-006818
Filed
May 10, 2022
Trade date
May 8-10, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.09M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mussallem Michael ACIK 0001204551Director, Officer (Chairman & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 8, 2022Common StockMOption exerciseAcquired+56,831$0.00F1$0157,352.82Direct
May 10, 2022Common StockMOption exerciseAcquired+45,050$21.76+$980,288202,402.82Direct
May 10, 2022Common StockSSaleDisposed−2,724$96.12F3−$261,830.88199,678.82Direct
May 10, 2022Common StockSSaleDisposed−4,700$93.41F4−$439,027194,978.82Direct
May 10, 2022Common StockSSaleDisposed−12,028$95.39F5−$1,147,350.92182,950.82Direct
May 10, 2022Common StockGGiftDisposed−12,500$0.00$0170,450.82Direct
May 10, 2022Common StockSSaleDisposed−13,098$94.54F6−$1,238,284.92157,352.82Direct
May 10, 2022Common StockGGiftAcquired+12,500$0.00$03,406,517Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 8, 2022Common StockMOption exerciseDisposed−56,831$0.00$048,712Direct
May 10, 2022Common StockMOption exerciseDisposed−45,050$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $95.905 to $96.470. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $92.880 to $93.880. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $94.900 to $95.900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $93.890 to $94.890. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)